Toxic Enforcement Act revisions
This article was originally published in The Rose Sheet
Executive Summary
California bill SB 1572, signed by Governor Gray Davis Aug. 30, would amend Prop 65 by requiring private litigants settling any alleged violation to submit to the state Attorney General a reporting form that includes the results of the settlement and final disposition of the case. Introduced Feb. 20 by Byron Sher (D-Stanford), the bill moved through the legislature without substantive amendment. SB 1572 will supplement the added controls on Prop 65 cases recently established by Sher's SB 471, enacted in October 2001. The state is in the process of implementing the law, which requires private litigants to produce a "certificate of merit" demonstrating good cause for seeking Prop 65 warnings (1"The Rose Sheet" May 13, 2002, p. 6)...
You may also be interested in...
Prop 65 Private Case “Merit” Data Availability To Defendants Urged
California's Proposition 65 should allow prospective defendants early access to data supporting "certificates of merit" filed in support of private enforcement cases, the Cosmetic, Toiletry and Fragrance Association says in April 26 comments to the state attorney general's office
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.